Ramos, Carlos A <br/><br/>
Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes.  [electronic resource] 

 -  The Journal of clinical investigation  Sep 2017 
 - 3462-3471 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article 
<br/><br/><label>ISSN: </label>1558-8238 
<br/><br/><label>Standard No.: </label>10.1172/JCI94306  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antineoplastic Agents--chemistry<br/>Brentuximab Vedotin<br/>CD28 Antigens--chemistry<br/>Disease Progression<br/>Dose-Response Relationship, Drug<br/>Female<br/>Hodgkin Disease--immunology<br/>Humans<br/>Immunoconjugates--administration & dosage<br/>Immunophenotyping<br/>Ki-1 Antigen--metabolism<br/>Lymphoma, Large-Cell, Anaplastic--immunology<br/>Male<br/>Middle Aged<br/>Molecular Targeted Therapy<br/>Neoplasm Recurrence, Local<br/>Receptors, Antigen, T-Cell--chemistry<br/>T-Lymphocytes--cytology<br/>Transplantation Conditioning<br/>Treatment Outcome<br/>Young Adult